726812

```
         67699 STEM
        264494 CELL?
L1         514 STEM(W)CELL?
=> s l1 and neur?

         13196 NEUR?
L2         120 L1 AND NEUR?
=> s l2 and growth(w)factor?
         92415 GROWTH
        303697 FACTOR?
          3361 GROWTH(W)FACTOR?
L3          54 L2 AND GROWTH(W)FACTOR?
=> s l3 and egf
           501 EGF
L4           7 L3 AND EGF
=> d l4 1-7 cit,ab
```

1. 5,262,319, Nov. 16, 1993, Method for obtaining bone marrow free of tumor cells using transforming **growth** **factor** .beta.3; Kenneth K. Iwata, et al., 435/240.2, 240.25; 530/399 [IMAGE AVAILABLE]

US PAT NO: 5,262,319 [IMAGE AVAILABLE] L4: 1 of 7

ABSTRACT:
The present invention provides (1) an antibody which (a) specifically binds to human TGF-.beta.3 and (b) exhibits substantially no cross reactivity with TGF-.beta.1 or TGF-.beta.2 and (2) antibodies directed against the pro region of the TGF-.beta. precursor. Further, this invention provides a pharmaceutical composition comprising the pro region of the TGF-.beta. precursor. Also, this invention provides methods for diagnosing, detecting and treating subjects suffering from disorders associated with TGF-.beta.3.

2. 5,262,308, Nov. 16, 1993, Cell lines which constitutively express IGF-1 and IGF-1 R; Renato Baserga, 435/69.1, 172.3, 240.2, 320.1 [IMAGE AVAILABLE]

US PAT NO: 5,262,308 [IMAGE AVAILABLE] L4: 2 of 7

ABSTRACT:
Cells which constitutively express IGF-1 and IGF-1 R cDNAs are provided. These cells are useful for the production of selected proteins. Methods for producing the cells are also provided. Diagnostic and therapeutic methods are provided using cells transfected with IGF-1 R.

3. 5,256,642, Oct. 26, 1993, Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof; Douglas T. Fearon, et al., 514/8; 424/94.63, 94.64; 435/215, 216; 514/2; 530/350 [IMAGE AVAILABLE]

US PAT NO: 5,256,642 [IMAGE AVAILABLE] L4: 3 of 7

ABSTRACT:
The present invention relates to compositions comprising soluble complement receptor 1 (CR1) and a thrombolytic agent. In a specific embodiment, the thrombolytic agent is anisoylated human plasminogen-streptokinase activator complex (ASPAC). The invention further relates to methods for treating thrombotic conditions in humans and animals by administering a composition comprising soluble CR1 and a thrombolytic agent. In particular, the compositions and methods are useful both for reducing reperfusion injury and ameliorating the other effects of myocardial infarction.

4. 5,198,356, Mar. 30, 1993, Monophenotypic in vitro cell lines of megakaryocytic lineage, products produced thereby and methods; Michael A. Lieberman, et al., 435/240.2, 240.1, 240.23 [IMAGE AVAILABLE]

US PAT NO: 5,198,356 [IMAGE AVAILABLE] L4: 4 of 7

ABSTRACT:
Human monophenotypic cloned cell lines of megakaryocytic lineage are established in vitro through use of adherent stromal cells in long term human bone marrow culture. Long term bone marrow cultures are used for initial adaptation of the cells to culture conditions. Once adapted, cells of the human in vitro cell lines are weaned from the stromal layer until they proliferate in the complete absence of any feeder layer. Seed cells for establishment of human in vitro cell lines were derived from a human solid tumor designated as ATCC CRL 9139 xenograft. Cells of one cloned in vitro cell line designated as CHRF-288-11 exhibits a karyotype and markers characteristic of megakaryocytes and platelets. Cells of the CHRF-288-11 cell line express platelet peroxidate, platelet factor IV, platelet Ca.sup.++ -ATPase, gpIIbIIIa, factor VIII, and MY7, MY9 and HLA-Dr antigens. CHRF-288-11 cell line exhibits a constant karyotype (50, XY). CHRF-288-11 cell line is deposited under the Budapest Treaty with American Type Culture Collection, 12301 Parklawn Drive, Rockville, Md. 20852, under accession No. CRL 10107.

5. 4,980,286, Dec. 25, 1990, In vivo introduction and expression of foreign genetic material in epithelial cells; Jeffrey R. Morgan, et al., 435/172.3, 69.1, 70.1, 70.3, 172.1, 240.1, 240.2; 935/59, 62, 66, 70, 71 [IMAGE AVAILABLE]

US PAT NO: 4,980,286 [IMAGE AVAILABLE] L4: 5 of 7

ABSTRACT:
Epithelial cells expressing foreign genetic material are described. The foreign genetic material can be DNA or RNA which does not occur in epithelial cells; DNA or RNA which occurs in epithelial cells but is not expressed in them at levels which are biologically significant; DNA or RNA which occurs in epithelial and has been modified so that it is expressed in epithelial cells; and any DNA or RNA which can be modified to be expressed in epithelial cells, alone or in any combination thereof. In addition, epithelial cells of the present invention can express genetic material encoding a selectable marker by which cells expressing the foreign genetic material can be expressed.

6. 4,868,116, Sep. 19, 1989, Introduction and expression of foreign genetic material in epithelial cells; Jeffrey R. Morgan, et al.,

435/240.2, 172.3, 948; 536/23.1, 23.2, 23.51 [IMAGE AVAILABLE]

US PAT NO: 4,868,116 [IMAGE AVAILABLE] L4: 6 of 7

ABSTRACT:
Epithelial cells expressing foreign genetic material are described. The foreign genetic material can be DNA or RNA which does not occur in epithelial cells; DNA or RNA which occurs in epithelial cells but is not expressed in them at levels which are biologically significant; DNA or RNA which occurs in epithelial and has been modified so that it is expressed in epithelial cells; and any DNA or RNA which can be modified to be expressed in epithelial cells, alone or in any combination thereof. In addition, epithelial cells of the present invention can express genetic material encoding a selectable marker by which cells expressing the foreign genetic material can be expressed.

7. 4,808,402, Feb. 28, 1989, Method and compositions for modulating neovascularization; Samuel J. Leibovich, et al., 424/78.06, 85.1, 423, 618; 514/2, 8, 21 [IMAGE AVAILABLE]

US PAT NO: 4,808,402 [IMAGE AVAILABLE] L4: 7 of 7

ABSTRACT:
Tumor necrosis factors possess the unexpected ability to induce angiogenesis, or neovascularization. Novel methods and TNF-containing compositions and articles are provided for the induction of neovascularization and rapid wound healing.

```
=> e weiss, samuel/n
E2        1524     WEISS/BI
'N' IS NOT A RECOGNIZED COMMAND
=> e weiss, samuel/in
E1           6     WEISS, RUDOLF/IN
E2           2     WEISS, SAM/IN
E3           2 --> WEISS, SAMUEL/IN
E4           1     WEISS, SAMUEL HERMAN/IN
E5           1     WEISS, SAMUEL M/IN
E6           1     WEISS, SCOTT A/IN
E7           1     WEISS, SHELDON M/IN
E8           1     WEISS, SHERMAN L/IN
E9           1     WEISS, SHIMON/IN
E10          1     WEISS, SHIRLEY I/IN
E11          1     WEISS, SHIRLEY I DECEASED/IN
E12          4     WEISS, SIDNEY/IN
=> s e3
L5           2 "WEISS, SAMUEL"/IN
=> d l5 1-2 cit,ab
```

1. D 270,726, Sep. 27, 1983, Miniature telephone enclosure; **Samuel Weiss**, D14/143; D25/16 [IMAGE AVAILABLE]

US PAT NO: D 270,726 [IMAGE AVAILABLE] L5: 1 of 2

2. 4,381,288, Apr. 26, 1983, Mercury brine sludge treatment; **Samuel Weiss**, et al., 423/101; 210/901; 423/109 [IMAGE AVAILABLE]

US PAT NO: 4,381,288 [IMAGE AVAILABLE] L5: 2 of 2

ABSTRACT:
A process is provided for treating brine sludge to render it suitable for ecologically safe disposal by removing therefrom leachable mercury impurities. The process comprises dewatering the sludge and conveying the dewatered sludge through a series of water washings to remove therefrom leachable mercury to render it suitable for land fill disposal.

```
=> s e4,e5
             1 "WEISS, SAMUEL HERMAN"/IN
             1 "WEISS, SAMUEL M"/IN
L6           2 ("WEISS, SAMUEL HERMAN"/IN OR "WEISS, SAMUEL M"/IN)
=> d l6 1-2 cit

1.  D 287,909, Jan. 27, 1987, Recreational lounge; **Samuel M. Weiss**,
D6/329, 360, 382, 386; D21/235 [IMAGE AVAILABLE]

2.  3,769,920, Nov. 6, 1973, FOLDING TABLE LEG LOCKING DEVICE; **Samuel
Herman Weiss**, 108/133 [IMAGE AVAILABLE]
=> e reynolds, brent a./in
E1           1     REYNOLDS, BLAKE W/IN
E2           1     REYNOLDS, BRADLEY D/IN
E3           0 --> REYNOLDS, BRENT A/IN
E4           1     REYNOLDS, BRETT S/IN
E5           1     REYNOLDS, BRIAN C/IN
E6           2     REYNOLDS, BRIAN E/IN
E7           1     REYNOLDS, BRIAN L/IN
E8           1     REYNOLDS, BRIAN R/IN
E9           5     REYNOLDS, BRUCE A/IN
E10          1     REYNOLDS, BRUCE C/IN
E11          8     REYNOLDS, BRUCE E/IN
E12          1     REYNOLDS, BRUCE R/IN
=> log y
U.S. Patent & Trademark Office LOGOFF AT 14:13:27 ON 31 JAN 94
+++
OK
ATZ
ATZ
OK
ATH
ATH
OK
```